Cryoprecipitated-Antihemophilic Factor

PreclinicalBiologic

Cryoprecipitated-Antihemophilic Factor is one of 53 biologic programs targeting Hemorrhage. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageActive, not recruiting

HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Plavix

Klor-Con

Bayer Aspirin

Eliquis

Prevacid

Savaysa

Ketalar

1 8

Decadron

AAspen Global Incorporated

Approved

1 9

Coumadin

AAbbott

Approved

1 10

Celebrex

PPhiladelphia Eye Associates

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Not yet recruiting

Hemorrhage

NCT07218185

Clinical

Trials by Indication[1]

Hemorrhage1 trial

Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage

Not yet recruiting·CCerus Corporation··NCT07218185·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cryoprecipitated-Antihemophilic Factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cryoprecipitated-Antihemophilic Factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cryoprecipitated-Antihemophilic Factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cerus Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCerus Corporation

Cryoprecipitated-Antihemophilic Factor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News